Eintrag weiter verarbeiten
Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia
Gespeichert in:
| Zeitschriftentitel: | British Journal of Haematology |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , |
| In: | British Journal of Haematology, 147, 2009, 4, S. 507-514 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Blum, Kristie A. Advani, Anjani Fernandez, Louis Van Der Jagt, Richard Brandwein, Joseph Kambhampati, Suman Kassis, Jeannine Davis, Melanie Bonfils, Claire Dubay, Marja Dumouchel, Julie Drouin, Michel Lucas, David M. Martell, Robert E. Byrd, John C. Blum, Kristie A. Advani, Anjani Fernandez, Louis Van Der Jagt, Richard Brandwein, Joseph Kambhampati, Suman Kassis, Jeannine Davis, Melanie Bonfils, Claire Dubay, Marja Dumouchel, Julie Drouin, Michel Lucas, David M. Martell, Robert E. Byrd, John C. |
|---|---|
| author |
Blum, Kristie A. Advani, Anjani Fernandez, Louis Van Der Jagt, Richard Brandwein, Joseph Kambhampati, Suman Kassis, Jeannine Davis, Melanie Bonfils, Claire Dubay, Marja Dumouchel, Julie Drouin, Michel Lucas, David M. Martell, Robert E. Byrd, John C. |
| spellingShingle |
Blum, Kristie A. Advani, Anjani Fernandez, Louis Van Der Jagt, Richard Brandwein, Joseph Kambhampati, Suman Kassis, Jeannine Davis, Melanie Bonfils, Claire Dubay, Marja Dumouchel, Julie Drouin, Michel Lucas, David M. Martell, Robert E. Byrd, John C. British Journal of Haematology Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia Hematology |
| author_sort |
blum, kristie a. |
| spelling |
Blum, Kristie A. Advani, Anjani Fernandez, Louis Van Der Jagt, Richard Brandwein, Joseph Kambhampati, Suman Kassis, Jeannine Davis, Melanie Bonfils, Claire Dubay, Marja Dumouchel, Julie Drouin, Michel Lucas, David M. Martell, Robert E. Byrd, John C. 0007-1048 1365-2141 Wiley Hematology http://dx.doi.org/10.1111/j.1365-2141.2009.07881.x <jats:title>Summary</jats:title><jats:p>MGCD0103, an orally available class I histone deacetylase (HDAC) inhibitor, was examined for pre‐clinical activity in chronic lymphocytic leukaemia (CLL). A phase II clinical trial was performed, starting at a dose of 85 mg/d, three times per week. Dose escalation to 110 mg or the addition of rituximab was permitted in patients without a response after two or more cycles. MGCD0103 demonstrated pre‐clinical activity against CLL cells with a LC<jats:sub>50</jats:sub> (concentration lethal to 50%) of 0·23 μmol/l and increased acetylation of the HDAC class I specific target histone H3. Twenty‐one patients received a median of two cycles of MGCD0103 (range, 0–12). All patients had previously received fludarabine, 33% were fludarabine refractory, and 71% had del(11q22·3) or del(17p13·1). No responses according to the National Cancer Institutes 1996 criteria were observed. Three patients received 110 mg and four patients received concomitant rituximab, with no improvement in response. Grade 3–4 toxicity consisted of infections, thrombocytopenia, anaemia, diarrhoea, and fatigue. HDAC inhibition was observed in six out of nine patients on day 8. Limited activity was observed with single agent MGCD0103 in high risk patients with CLL. Future investigations in CLL should focus on broad HDAC inhibition, combination strategies, and approaches to diminish constitutional symptoms associated with this class of drugs.</jats:p> Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia British Journal of Haematology |
| doi_str_mv |
10.1111/j.1365-2141.2009.07881.x |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjEzNjUtMjE0MS4yMDA5LjA3ODgxLng |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjEzNjUtMjE0MS4yMDA5LjA3ODgxLng |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
Wiley, 2009 |
| imprint_str_mv |
Wiley, 2009 |
| issn |
0007-1048 1365-2141 |
| issn_str_mv |
0007-1048 1365-2141 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
blum2009phaseiistudyofthehistonedeacetylaseinhibitormgcd0103inpatientswithpreviouslytreatedchroniclymphocyticleukaemia |
| publishDateSort |
2009 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
British Journal of Haematology |
| source_id |
49 |
| title |
Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia |
| title_unstemmed |
Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia |
| title_full |
Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia |
| title_fullStr |
Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia |
| title_full_unstemmed |
Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia |
| title_short |
Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia |
| title_sort |
phase ii study of the histone deacetylase inhibitor mgcd0103 in patients with previously treated chronic lymphocytic leukaemia |
| topic |
Hematology |
| url |
http://dx.doi.org/10.1111/j.1365-2141.2009.07881.x |
| publishDate |
2009 |
| physical |
507-514 |
| description |
<jats:title>Summary</jats:title><jats:p>MGCD0103, an orally available class I histone deacetylase (HDAC) inhibitor, was examined for pre‐clinical activity in chronic lymphocytic leukaemia (CLL). A phase II clinical trial was performed, starting at a dose of 85 mg/d, three times per week. Dose escalation to 110 mg or the addition of rituximab was permitted in patients without a response after two or more cycles. MGCD0103 demonstrated pre‐clinical activity against CLL cells with a LC<jats:sub>50</jats:sub> (concentration lethal to 50%) of 0·23 μmol/l and increased acetylation of the HDAC class I specific target histone H3. Twenty‐one patients received a median of two cycles of MGCD0103 (range, 0–12). All patients had previously received fludarabine, 33% were fludarabine refractory, and 71% had del(11q22·3) or del(17p13·1). No responses according to the National Cancer Institutes 1996 criteria were observed. Three patients received 110 mg and four patients received concomitant rituximab, with no improvement in response. Grade 3–4 toxicity consisted of infections, thrombocytopenia, anaemia, diarrhoea, and fatigue. HDAC inhibition was observed in six out of nine patients on day 8. Limited activity was observed with single agent MGCD0103 in high risk patients with CLL. Future investigations in CLL should focus on broad HDAC inhibition, combination strategies, and approaches to diminish constitutional symptoms associated with this class of drugs.</jats:p> |
| container_issue |
4 |
| container_start_page |
507 |
| container_title |
British Journal of Haematology |
| container_volume |
147 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792340483725328384 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:04:44.582Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Phase+II+study+of+the+histone+deacetylase+inhibitor+MGCD0103+in+patients+with+previously+treated+chronic+lymphocytic+leukaemia&rft.date=2009-11-01&genre=article&issn=1365-2141&volume=147&issue=4&spage=507&epage=514&pages=507-514&jtitle=British+Journal+of+Haematology&atitle=Phase+II+study+of+the+histone+deacetylase+inhibitor+MGCD0103+in+patients+with+previously+treated+chronic+lymphocytic+leukaemia&aulast=Byrd&aufirst=John+C.&rft_id=info%3Adoi%2F10.1111%2Fj.1365-2141.2009.07881.x&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792340483725328384 |
| author | Blum, Kristie A., Advani, Anjani, Fernandez, Louis, Van Der Jagt, Richard, Brandwein, Joseph, Kambhampati, Suman, Kassis, Jeannine, Davis, Melanie, Bonfils, Claire, Dubay, Marja, Dumouchel, Julie, Drouin, Michel, Lucas, David M., Martell, Robert E., Byrd, John C. |
| author_facet | Blum, Kristie A., Advani, Anjani, Fernandez, Louis, Van Der Jagt, Richard, Brandwein, Joseph, Kambhampati, Suman, Kassis, Jeannine, Davis, Melanie, Bonfils, Claire, Dubay, Marja, Dumouchel, Julie, Drouin, Michel, Lucas, David M., Martell, Robert E., Byrd, John C., Blum, Kristie A., Advani, Anjani, Fernandez, Louis, Van Der Jagt, Richard, Brandwein, Joseph, Kambhampati, Suman, Kassis, Jeannine, Davis, Melanie, Bonfils, Claire, Dubay, Marja, Dumouchel, Julie, Drouin, Michel, Lucas, David M., Martell, Robert E., Byrd, John C. |
| author_sort | blum, kristie a. |
| container_issue | 4 |
| container_start_page | 507 |
| container_title | British Journal of Haematology |
| container_volume | 147 |
| description | <jats:title>Summary</jats:title><jats:p>MGCD0103, an orally available class I histone deacetylase (HDAC) inhibitor, was examined for pre‐clinical activity in chronic lymphocytic leukaemia (CLL). A phase II clinical trial was performed, starting at a dose of 85 mg/d, three times per week. Dose escalation to 110 mg or the addition of rituximab was permitted in patients without a response after two or more cycles. MGCD0103 demonstrated pre‐clinical activity against CLL cells with a LC<jats:sub>50</jats:sub> (concentration lethal to 50%) of 0·23 μmol/l and increased acetylation of the HDAC class I specific target histone H3. Twenty‐one patients received a median of two cycles of MGCD0103 (range, 0–12). All patients had previously received fludarabine, 33% were fludarabine refractory, and 71% had del(11q22·3) or del(17p13·1). No responses according to the National Cancer Institutes 1996 criteria were observed. Three patients received 110 mg and four patients received concomitant rituximab, with no improvement in response. Grade 3–4 toxicity consisted of infections, thrombocytopenia, anaemia, diarrhoea, and fatigue. HDAC inhibition was observed in six out of nine patients on day 8. Limited activity was observed with single agent MGCD0103 in high risk patients with CLL. Future investigations in CLL should focus on broad HDAC inhibition, combination strategies, and approaches to diminish constitutional symptoms associated with this class of drugs.</jats:p> |
| doi_str_mv | 10.1111/j.1365-2141.2009.07881.x |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjEzNjUtMjE0MS4yMDA5LjA3ODgxLng |
| imprint | Wiley, 2009 |
| imprint_str_mv | Wiley, 2009 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 0007-1048, 1365-2141 |
| issn_str_mv | 0007-1048, 1365-2141 |
| language | English |
| last_indexed | 2024-03-01T16:04:44.582Z |
| match_str | blum2009phaseiistudyofthehistonedeacetylaseinhibitormgcd0103inpatientswithpreviouslytreatedchroniclymphocyticleukaemia |
| mega_collection | Wiley (CrossRef) |
| physical | 507-514 |
| publishDate | 2009 |
| publishDateSort | 2009 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | British Journal of Haematology |
| source_id | 49 |
| spelling | Blum, Kristie A. Advani, Anjani Fernandez, Louis Van Der Jagt, Richard Brandwein, Joseph Kambhampati, Suman Kassis, Jeannine Davis, Melanie Bonfils, Claire Dubay, Marja Dumouchel, Julie Drouin, Michel Lucas, David M. Martell, Robert E. Byrd, John C. 0007-1048 1365-2141 Wiley Hematology http://dx.doi.org/10.1111/j.1365-2141.2009.07881.x <jats:title>Summary</jats:title><jats:p>MGCD0103, an orally available class I histone deacetylase (HDAC) inhibitor, was examined for pre‐clinical activity in chronic lymphocytic leukaemia (CLL). A phase II clinical trial was performed, starting at a dose of 85 mg/d, three times per week. Dose escalation to 110 mg or the addition of rituximab was permitted in patients without a response after two or more cycles. MGCD0103 demonstrated pre‐clinical activity against CLL cells with a LC<jats:sub>50</jats:sub> (concentration lethal to 50%) of 0·23 μmol/l and increased acetylation of the HDAC class I specific target histone H3. Twenty‐one patients received a median of two cycles of MGCD0103 (range, 0–12). All patients had previously received fludarabine, 33% were fludarabine refractory, and 71% had del(11q22·3) or del(17p13·1). No responses according to the National Cancer Institutes 1996 criteria were observed. Three patients received 110 mg and four patients received concomitant rituximab, with no improvement in response. Grade 3–4 toxicity consisted of infections, thrombocytopenia, anaemia, diarrhoea, and fatigue. HDAC inhibition was observed in six out of nine patients on day 8. Limited activity was observed with single agent MGCD0103 in high risk patients with CLL. Future investigations in CLL should focus on broad HDAC inhibition, combination strategies, and approaches to diminish constitutional symptoms associated with this class of drugs.</jats:p> Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia British Journal of Haematology |
| spellingShingle | Blum, Kristie A., Advani, Anjani, Fernandez, Louis, Van Der Jagt, Richard, Brandwein, Joseph, Kambhampati, Suman, Kassis, Jeannine, Davis, Melanie, Bonfils, Claire, Dubay, Marja, Dumouchel, Julie, Drouin, Michel, Lucas, David M., Martell, Robert E., Byrd, John C., British Journal of Haematology, Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia, Hematology |
| title | Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia |
| title_full | Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia |
| title_fullStr | Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia |
| title_full_unstemmed | Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia |
| title_short | Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia |
| title_sort | phase ii study of the histone deacetylase inhibitor mgcd0103 in patients with previously treated chronic lymphocytic leukaemia |
| title_unstemmed | Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia |
| topic | Hematology |
| url | http://dx.doi.org/10.1111/j.1365-2141.2009.07881.x |